13F-HR filed by Caligan Partners LP
Caligan Partners LP filed this 13F-HR for the quarter ended 2025-12-31, filed 2026-02-17, with 24 holding rows worth $1,214,792,770.
- Accession
- 0001420506-26-000584
- Filer
- CIK 1727492
- Filed
- 2026-02-17
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2025
A holdings report, 24 entries on the cover page, a total value of $1,214,792,770 stated on the cover page (in dollars after the unit check, H1), rows summing to $1,214,792,770 with VALUE read as dollars as filed, 13F file number 028-23096. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| LIQUIDIA CORPORATION COM NEW | 53635D202 | Stock | 8,118,892 | $280,020,585 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 1,451,924 | $195,799,211 | dollars as filed | |
| REVOLUTION MEDICINES INC COM | 76155X100 | Stock | 1,283,900 | $102,262,635 | dollars as filed | |
| MINERALYS THERAPEUTICS INC | 603170101 | COM | 2,772,654 | $100,619,614 | dollars as filed | |
| MINERALYS THERAPEUTICS INC | 603170101 | COM | 2,298,400 | $83,408,936 | dollars as filed | put |
| VAXCYTE INC COM | 92243G108 | Stock | 1,704,815 | $78,660,164 | dollars as filed | |
| EXELIXIS INC COM | 30161Q104 | Stock | 1,553,262 | $68,079,473 | dollars as filed | |
| ADMA BIOLOGICS INC | 000899104 | COM | 3,012,508 | $54,948,146 | dollars as filed | |
| TANGO THERAPEUTICS INC | 87583X109 | COM | 3,729,895 | $33,046,870 | dollars as filed | |
| INHIBRX BIOSCIENCES INC | 45720N103 | COM | 323,565 | $25,561,635 | dollars as filed | |
| TYRA BIOSCIENCES INC | 90240B106 | COMMON STOCK | 944,257 | $24,824,517 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 549,700 | $24,637,554 | dollars as filed | put |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 549,665 | $24,635,985 | dollars as filed | |
| MAZE THERAPEUTICS INC COM | 578784100 | Stock | 550,191 | $22,794,413 | dollars as filed | |
| RAPT THERAPEUTICS INC | 75382E208 | COM NEW | 644,400 | $21,825,828 | dollars as filed | |
| AVALO THERAPEUTICS INC | 05338F306 | COMMON STOCK | 881,533 | $16,008,639 | dollars as filed | |
| ANIKA THERAPEUTICS INC | 035255108 | COM | 1,435,130 | $13,791,599 | dollars as filed | |
| INHIBRX BIOSCIENCES INC | 45720N103 | COM | 150,000 | $11,850,000 | dollars as filed | call |
| VOR BIOPHARMA INC | 929033207 | COMMON STOCK | 925,067 | $9,962,972 | dollars as filed | |
| INVENTIVA SA | 46124U107 | ADS | 2,000,000 | $9,300,000 | dollars as filed | |
| VERRICA PHARMACEUTICALS INC | 92511W207 | COM SHS | 923,910 | $7,677,692 | dollars as filed | |
| AGIOS PHARMACEUTICALS INC | 00847X104 | COM | 90,000 | $2,449,800 | dollars as filed | call |
| SPRUCE BIOSCIENCES INC | 85209E208 | COM NEW | 20,514 | $1,786,975 | dollars as filed | |
| ELEDON PHARMACEUTICALS INC | 28617k101 | COM | 555,978 | $839,527 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001420506-26-000584 | this filing | 2026-02-17 | acceptance time not in the bulk data set |